Perrigo Company plc (PRGON.MX)
| Previous Close | 686.00 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 687.00 - 687.00 |
| 52 Week Range | 687.00 - 687.00 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.49 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Perrigo (NYSE:PRGO) Is Due To Pay A Dividend Of $0.276
The board of Perrigo Company plc ( NYSE:PRGO ) has announced that it will pay a dividend on the 18th of June, with...
PR NewswirePerrigo Announces Quarterly Dividend
Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on June 18, 2024, to shareholders of record on May 31, 2024.
- PR Newswire
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
Perrigo Company plc (NYSE PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that pharmaceutical company Esteve Healthcare, S.L. ("ESTEVE") has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to €275 million, consisting of an upfront cash payment of €190 million and up to €85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.
